Abstract: Influenza vaccines are administered using solid biodegradable microneedles. The microneedles are fabricated from the influenza vaccine in combination with solid excipient(s) and, after penetrating the skin, they dissolve in situ and release the vaccine to the immune system. The influenza vaccine is (i) a purified influenza virus surface antigen vaccine, rather than a live vaccine or a whole-virus or split inactivated vaccine (ii) an influenza vaccine prepared from viruses grown in cell culture, not eggs, (iii) a monovalent influenza vaccine e.g. for immunising against a pandemic strain, (iv) a bivalent vaccine, (v) a tetravalent or >4-valent vaccine, (vi) a mercury-free vaccine, or (vii) a gelatin-free vaccine.

Abstract: Various methods and systems are provided for reducing beam hardening artifacts and metal artifacts present in images generated with a dual-energy computed tomography (CT) scan protocol. In one embodiment, a method may include obtaining projection data of a region of interest (ROI) of a subject, the projection data acquired at two different x-ray tube energy levels, generating a first monoenergetic image at a first energy level from the projection data, generating a second monoenergetic image at a second energy level from the projection data, subtracting the first monoenergetic image from the second monoenergetic image to obtain a subtracted image, and outputting the subtracted image for display and/or storage.

Abstract: Influenza vaccines are administered using solid-biodegradable microneedles. The microneedles are fabricated from the influenza vaccine in combination with solid excipient(s) and, after penetrating the skin, they dissolve in situ and release the vaccine to the immune system. The influenza vaccine is (i) a purified influenza virus surface antigen vaccine, rather than a live vaccine or a whole-virus or split inactivated vaccine (ii) an influenza vaccine prepared from viruses grown in cell culture, not eggs, (iii) a monovalent influenza vaccine e.g. for immunising against a pandemic strain, (iv) a bivalent vaccine, (v) a tetravalent or >valent vaccine, (vi) a mercury-free vaccine, or (vii) a gelatin free vaccine.

Abstract: An improved and high capacity gas igniter for furnaces and burners. The igniter can include an igniter tip that is annular in shape and includes various holes of different sizes and angular projections distributed throughout. The igniter tip may utilize a slip-joint-like mechanism or sleeve that connects inner and outer tubes of a guide tube that allows the inner tube to slide when undergoing thermal expansion. This configuration alleviates stress from building up on the inner tube and igniter tip, preventing damage.

Abstract: Provided herein are systems and methods to measure the intraocular pressure, ocular tissue geometry and the biomechanical properties of an ocular tissue, such as an eye-globe or cornea, in one instrument. The system is an optical coherence tomography subsystem and an applanation tonometer subsystem housed as one instrument and interfaced with a computer for at least data processing and image display. The system utilizes an air-puff and a focused micro air-pulse to induce deformation and applanation and displacement in the ocular tissue. Pressure profiles of the air puff with applanation times are utilized to measure intraocular pressure. Temporal profiles of displacement and/or spatio-temporal profiles of a displacement-generated elastic wave are analyzed to calculate biomechanical properties.

Abstract: Influenza vaccines are administered using solid biodegradable microneedles. The microneedles are lubricated from the influenza vaccine in combination with solid excipient(s) and, after penetrating the skin, they dissolve in situ and release the vaccine to the immune system. The influenza vaccine is (i) a purified influenza virus surface antigen vaccine, rather than a live vaccine or a whole-virus or split inactivated vaccine (ii) an influenza vaccine prepared from viruses grown in cell culture, not eggs, (iii) a monovalent influenza vaccine e.g. for immunising against a pandemic strain, (iv) a bivalent vaccine, (v) a tetravalent or >4 -valent vaccine, (vi) mercury-free vaccine, or (vii) a gelatin-free vaccine.

Abstract: Methods and systems for providing depth-resolved real-time visual feedback to a physician during cosmetic dermal filler injections with micrometer spatial resolution utilizing a noninvasive optical coherence tomography/elastography, 2D-3D virtual and real time system. This system can be automated to direct proper volumes and viscosity of the necessary injection substances. The methods and systems allow for assessment of the elasticity of the tissue before and after the injection to evaluate the efficacy of the injection, with predetermined virtual results before and matched post injection images. The elasticity assessment method preferably utilizes a focused air-pulse to induce a micrometer scale displacement in the skin and the optical coherence tomography system to image this displacement. By utilizing a model-based reconstruction method, the viscoelasticity of the tissue at a specific measurement position can be obtained and virtual and post injection real time projections can be imaged.

Abstract: Aspects of the disclosure relate to using synthetic DNA stranding and mutant nucleotide processes to conduct enterprise market volatility predictions. In some embodiments, a computing platform may initiate a set of instructions associated with performing an action on a synthetic DNA market data set associated with a plurality of lines of business across an enterprise organization. Thereafter, the computing platform may convert the set of instructions to a mutant nucleotide sequence, and insert the mutant nucleotide sequence into the synthetic DNA market data set. The computing platform may extract, using the mutant nucleotide sequence, target information from the synthetic DNA market data set, and validate the target information to detect one or more anomalies. The computing platform may remove the one or more data anomalies, and subsequently output a validated synthetic DNA market data set to a synthetic DNA client server.

Abstract: Aspects of the disclosure relate to using synthetic DNA stranding and mutant nucleotide processes to conduct enterprise market volatility predictions. In some embodiments, a computing platform may receive raw market data from a plurality of lines of business of an enterprise organization. Thereafter, the computing platform may preprocess the raw market data to obtain enterprise level market data, execute synthetic DNA stranding of the enterprise level market data to obtain synthetic DNA stranded market data, run the synthetic DNA stranded market data through one or more market volatility models, and compile results from the market volatility models on the synthetic DNA stranded market data. The computing platform may transmit results from the market volatility models on the synthetic DNA stranded market data. The transmitted results may be configured to display a market application interface that includes market volatility forecasting parameters based on results of the market volatility models.

Abstract: Aspects of the disclosure relate to using synthetic DNA stranding and mutant nucleotide processes to conduct enterprise market volatility predictions. In some embodiments, a computing platform may receive market data from a plurality of lines of business across an enterprise, wherein the market data is received in a raw, uncompressed format. Thereafter, the computing platform may assimilate and preprocess the market data to output vectored market data. The computing platform may perform a synthetic DNA stranding process on the vectored market data to create one or more strands of synthetic DNA market data, and output the one or more strands of synthetic DNA market data to a synthetic DNA client server, wherein the one or more stands of synthetic DNA market data is configured for input in a market volatility prediction model.

Abstract: A system and method for measuring biomechanical properties of tissues without external excitation are capable of measuring and quantifying these parameters of tissues in situ and in vivo. The system and method preferably utilize a phase-sensitive optical coherence tomography (OCT) system for measuring the displacement caused by the intrinsic heartbeat. The method allows noninvasive and nondestructive quantification of tissue mechanical properties. Preferably, the method is used to detect tissue stiffness and to evaluate its stiffness due to intrinsic pulsatile motion from the heartbeat. This noninvasive method can evaluate the biomechanical properties of the tissues in vivo for detecting the onset and progression of degenerative or other diseases and evaluating the efficacy of therapies.

Abstract: Provided herein are systems and methods to measure the intraocular pressure, ocular tissue geometry and the biomechanical properties of an ocular tissue, such as an eye-globe or cornea, in one instrument. The system is an optical coherence tomography subsystem and an applanation tonometer subsystem housed as one instrument and interfaced with a computer for at least data processing and image display. The system utilizes an air-puff and a focused micro air-pulse to induce deformation and applanation and displacement in the ocular tissue. Pressure profiles of the air puff with applanation times are utilized to measure intraocular pressure. Temporal profiles of displacement and/or spatio-temporal profiles of a displacement-generated elastic wave are analyzed to calculate biomechanical properties.

Abstract: Provided herein are systems and methods to measure the intraocular pressure, ocular tissue geometry and the biomechanical properties of an ocular tissue, such as an eye-globe or cornea, in one instrument. The system is an optical coherence tomography subsystem and an applanation tonometer subsystem housed as one instrument and interfaced with a computer for at least data processing and image display. The system utilizes an air-puff and a focused micro air-pulse to induce deformation and applanation and displacement in the ocular tissue. Pressure profiles of the air puff with applanation times are utilized to measure intraocular pressure. Temporal profiles of displacement and/or spatio-temporal profiles of a displacement-generated elastic wave are analyzed to calculate biomechanical properties.

Abstract: An improved and high capacity gas igniter for furnaces and burners. The igniter can include an igniter tip that is annular in shape and includes various holes of different sizes and angular projections distributed throughout. The igniter tip may utilize a slip-joint-like mechanism or sleeve that connects inner and outer tubes of a guide tube that allows the inner tube to slide when undergoing thermal expansion. This configuration alleviates stress from building up on the inner tube and igniter tip, preventing damage.

Abstract: A system and method for measuring biomechanical properties of tissues without external excitation are capable of measuring and quantifying these parameters of tissues in situ and in vivo. The system and method preferably utilize a phase-sensitive optical coherence tomography (OCT) system for measuring the displacement caused by the intrinsic heartbeat. The method allows noninvasive and nondestructive quantification of tissue mechanical properties. Preferably, the method is used to detect tissue stiffness and to evaluate its stiffness due to intrinsic pulsatile motion from the heartbeat. This noninvasive method can evaluate the biomechanical properties of the tissues in vivo for detecting the onset and progression of degenerative or other diseases and evaluating the efficacy of therapies.

Abstract: Aspects of the disclosure relate to using synthetic DNA stranding and mutant nucleotide processes to conduct enterprise market volatility predictions. In some embodiments, a computing platform may initiate a set of instructions associated with performing an action on a synthetic DNA market data set associated with a plurality of lines of business across an enterprise organization. Thereafter, the computing platform may convert the set of instructions to a mutant nucleotide sequence, and insert the mutant nucleotide sequence into the synthetic DNA market data set. The computing platform may extract, using the mutant nucleotide sequence, target information from the synthetic DNA market data set, and validate the target information to detect one or more anomalies. The computing platform may remove the one or more data anomalies, and subsequently output a validated synthetic DNA market data set to a synthetic DNA client server.

Abstract: Aspects of the disclosure relate to using synthetic DNA stranding and mutant nucleotide processes to conduct enterprise market volatility predictions. In some embodiments, a computing platform may receive raw market data from a plurality of lines of business of an enterprise organization. Thereafter, the computing platform may preprocess the raw market data to obtain enterprise level market data, execute synthetic DNA stranding of the enterprise level market data to obtain synthetic DNA stranded market data, run the synthetic DNA stranded market data through one or more market volatility models, and compile results from the market volatility models on the synthetic DNA stranded market data. The computing platform may transmit results from the market volatility models on the synthetic DNA stranded market data. The transmitted results may be configured to display a market application interface that includes market volatility forecasting parameters based on results of the market volatility models.

Abstract: Aspects of the disclosure relate to using synthetic DNA stranding and mutant nucleotide processes to conduct enterprise market volatility predictions. In some embodiments, a computing platform may receive market data from a plurality of lines of business across an enterprise, wherein the market data is received in a raw, uncompressed format. Thereafter, the computing platform may assimilate and preprocess the market data to output vectored market data. The computing platform may perform a synthetic DNA stranding process on the vectored market data to create one or more strands of synthetic DNA market data, and output the one or more strands of synthetic DNA market data to a synthetic DNA client server, wherein the one or more stands of synthetic DNA market data is configured for input in a market volatility prediction model.

Abstract: Systems, computer program products, and methods are described herein for testing application resiliency via context aware auditing equilibrium. The present invention is configured to receive an indication to test application resiliency of an application; initiate a resiliency test engine on the application; determine, using the resiliency test engine, one or more artifacts associated with the application to be tested; determine a first subset of the one or more test scripts is able to capture a behavior of a first subset of the one or more artifacts; initiate a context-based classification engine on the first subset of the one or more test scripts and the first subset of the one or more artifacts; classify the first subset of the one or more test scripts into a supporting behavior class and an opposing behavior class; generate a graphical representation of the classification; and display the graphical representation of the classification.

Abstract: A system and method for measuring biomechanical properties of tissues without external excitation are capable of measuring and quantifying these parameters of tissues in situ and in vivo. The system and method preferably utilize a phase-sensitive optical coherence tomography (OCT) system for measuring the displacement caused by the intrinsic heartbeat. The method allows noninvasive and nondestructive quantification of tissue mechanical properties. Preferably, the method is used to detect tissue stiffness and to evaluate its stiffness due to intrinsic pulsatile motion from the heartbeat. This noninvasive method can evaluate the biomechanical properties of the tissues in vivo for detecting the onset and progression of degenerative or other diseases and evaluating the efficacy of therapies.